We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gut Microbiota Differ in Men With Prostate Cancer

By LabMedica International staff writers
Posted on 06 Jul 2022
Image: Petri dish culture plate with bacterial colonial growth of Prevotella spp., The men with cancer had increased levels Prevotella-9 (Photo courtesy of Dr. V.R. Dowell)
Image: Petri dish culture plate with bacterial colonial growth of Prevotella spp., The men with cancer had increased levels Prevotella-9 (Photo courtesy of Dr. V.R. Dowell)

Gut microbiota are the collection of microbes in the gastrointestinal tract and they affect processes and mechanisms in the body. The state of gut microbiota has been linked to many conditions, even in organs that are far from the intestines, but their role in prostate cancer is not understood.

Prostate cancer is the most common male cancer globally, but varying rates in different parts of the world are little understood. It is common in most Western countries and less common elsewhere. Though it is known to be hereditary, there is evidence that men who emigrated from low to high incidence areas have increased risk of prostate cancer in their lifetimes, and their offspring have the risk of the high incidence region.

Clinical Urologists at theUniver sity of Turku (Turku, Finland) and their colleagues used samples collected from patients on a prospective multi-center clinical study. They sequenced the gut microbiota of 181 men who were suspected to have prostate cancer and undergoing prostate cancer diagnostics. The microbiota samples were collected at the time of their prostate biopsies after MRI scans.

The investigators reported that 60% of the men were diagnosed with prostate cancer, and their gut microbiota profiles were significantly different to those who had benign biopsies. The men with cancer had increased levels of Prevotella 9, members of the family Erysipelotrichaceae, and Escherichia-Shigella, a pathogen that causes diarrhea. They also had lower levels of Jonquetella, Moryella, Anaeroglobus, Corynebacterium and Clostridium sp., CAG-352 than men who had no cancer.

Peter Bostrom, MD, PhD, a Professor of Urology and lead author of the study, said, “There are significant variations in prostate cancer rates around the world, which could be due to genetic factors or differences in healthcare policies, but also variance in lifestyle and diet. The difference in gut microbiota between men with and without prostate cancer could underpin some of these variations. More studies are needed to look at the potential for using gut microbiota for both diagnostic and preventive strategies.” The study was presented at the European Association of Urology annual congress held July 1-4, 2022, in Amsterdam, the Netherlands.

Related Links:
University of Turku

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
All-in-One Molecular System
AIO M160
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.

Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more